Search PubMed⌕ Search

Biomedical subjects

G R Hanson

Publications and source records attributed to G R Hanson.

At least 55 records · Page 3Linked to original sources

Methamphetamine-induced rapid and reversible reduction in the activities of tryptophan hydroxylase and dopamine transporters: oxidative consequences?

Treatment with high doses of methamphetamine (METH) results in dramatic changes in extrapyramidal monoaminergic systems. Elevated concentrations of extracellular dopamine (DA), caused by METH administration, are thought to contribute to these effects due to the oxidative potential of this reactive catecholamine. According to this hypothesis monoaminergic cellular elements, which are vulnerable to oxidative modification, may be especially sensitive to high-dose METH treatments. We confirmed this possibility by observing that both tryptophan hydroxylase (the synthesizing enzyme for serotonin) and the DA transporter, proteins particularly susceptible to oxidative modification, were rapidly (within 30 min), but reversibly (returned to control levels by 36 hr) inactivated by a single administration of METH. These findings suggest that there also may be other cellular elements similarly altered by METH treatment due to oxidative mechanisms.

Animals↗

3-4-Methylenedioxymethamphetamine-induced acute changes in dopamine transporter function.

The acute effects of the amphetamine designer drug, 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy'), on dopamine transporter function in rat striatum were investigated and compared to other psychostimulants known to influence monoaminergic systems. A single MDMA injection (10-20 mg/kg; s.c.) caused a dose-related decrease in [3H]dopamine uptake into striatal synaptosomes prepared 1 h after MDMA administration. This rapid effect on [3H]dopamine uptake returned to control levels 24 h after treatment. A single administration of other amphetamine analogs, such as methamphetamine (15 mg/kg; s.c.), p-chloroamphetamine (10 mg/kg; i.p.) or methcathinone (30 mg/kg; s.c.), also rapidly decreased striatal [3H]dopamine uptake. In contrast, a single or multiple administrations of cocaine (30 mg/kg; i.p.) had no effect on [3H]dopamine transport into striatal synaptosomes. These changes in dopamine transporter activity by the amphetamine analogs may occur via reactive oxygen species-mediated mechanisms.

Animals↗

Computer simulation of magnetic resonance spectra employing homotopy.

Multidimensional homotopy provides an efficient method for accurately tracing energy levels and hence transitions in the presence of energy level anticrossings and looping transitions. Herein we describe the application and implementation of homotopy to the analysis of continuous wave electron paramagnetic resonance spectra. The method can also be applied to electron nuclear double resonance, electron spin echo envelope modulation, solid-state nuclear magnetic resonance, and nuclear quadrupole resonance spectra.

Computer Simulation↗

Oxygen radicals diminish dopamine transporter function in rat striatum.

Incubation of striatal synaptosomes with the oxygen radical generating enzyme, xanthine oxidase, decreased [3H]dopamine uptake: an effect attributable to a decreased Vmax. Concurrent incubation with the superoxide radical scavenger, superoxide dismutase, abolished the xanthine oxidase-induced decrease. These results indicate that, like methamphetamine administration in vivo, reactive oxygen species diminish dopamine transporter function in vitro. The significance of these findings to mechanisms responsible for effects of methamphetamine is discussed.

Animals↗

Differential effect of haloperidol on release of neurotensin in extrapyramidal and limbic systems.

The effect of the antipsychotic drug haloperidol on extracellular neurotensin-like immunoreactivity was investigated by microdialysis and compared with the time-dependent response of tissue neurotensin-like immunoreactivity content in brain structures containing dopamine nerve cell bodies and terminals. A single administration of haloperidol (1 mg/kg) increased the extracellular neurotensin-like immunoreactivity levels in nucleus accumbens as measured by microdialysis, but decreased its extracellular concentration in the caudate regions surrounding the probe. The same treatment increased the tissue content of neurotensin-like immunoreactivity in both the nucleus accumbens core and all caudate regions examined within 24 h after the injection. Interestingly, although the neurotensin-like immunoreactivity concentration in the substantia nigra was not altered by the haloperidol treatment, neurotensin-like immunoreactivity levels decreased significantly in the ventral tegmental area. These findings suggest that varied neurotensin systems are associated with nigrostriatal and mesolimbic dopamine pathways and these systems have different responses to haloperidol. The changes in the release of neurotensin may contribute to altered caudate and accumbens neurotensin-like immunoreactivity tissue content induced by haloperidol treatment, but other factors, such as variation in synthesis also likely influence these effects. Differential actions of haloperidol on neurotensin release might be due to regional differences in dopamine or sigma receptor subtypes associated with the neurotensin-containing neurons.

Animals↗

Characterisation of the pterin molybdenum cofactor in dimethylsulfoxide reductase of Rhodobacter capsulatus.

Analysis of dimethylsulfoxide reductase from Rhodobacter capsulatus showed that it contained 1 mol Mo and 2 mol GMP. This indicates that the molybdenum cofactor in dimethylsulfoxide reductase is bis(molybdopterin guanine dinucleotide) molybdenum. The absorption spectrum of the molybdopterin guanine dinucleotide released from dimethylsulfoxide reductase after denaturation of the holoenzyme was compared with those of pterin standards of known redox state. The spectra were most similar to pterin standards in the dihydro state and oxidised state. The reduction of 2,6-dichloroindophenol by molybdopterin guanine dinucleotide released from dimethylsulfoxide reductase and by pterin standards was also measured and approximately 2 mol electrons/2 mol molybdopterin guanine dinucleotide were found to reduce 2,6-dichloroindophenol. These results are consistent with the presence of one molybdopterin guanine dinucleotide moiety with a pyrazine ring at the oxidation level of a dihydropteridine and one molybdopterin guanine dinucleotide moiety with a pyrazine ring at the oxidation level of a fully aromatic pteridine. It is suggested that the pyrazine ring of Q-molybdopterin guanine dinucleotide is fully aromatic and contains a 5,6 double bond.

2,6-Dichloroindophenol↗

Methamphetamine-induced decrease in tryptophan hydroxylase activity: role of 5-hydroxytryptaminergic transporters.

Methamphetamine-induced 5-hydroxytryptaminergic neuronal damage purportedly involves transport of newly released dopamine from extracellular spaces into 5-hydroxytryptaminergic terminals. This hypothesis is based primarily on findings that dopamine is required for, whereas 5-hydroxytryptamine (5-HT) uptake inhibitors prevent, methamphetamine-induced deficits in 5-hydroxytryptaminergic neuronal function. This hypothesis is not, however, supported by findings presented in this study that 5-hydroxytryptaminergic neuronal damage, induced by p-chloroamphetamine, does not decrease [3H]dopamine uptake into rat brain synaptosomes prepared from 5-HT-transporter-containing tissue. Moreover, despite having greater affinity for the 5-HT transporter, citalopram has an IC50 for [1H]dopamine transport into these synaptosomal preparations that is considerably greater than that of fluoxetine. These data suggest that 5-HT transporters may not effect dopamine uptake and thereby methamphetamine-induced 5-hydroxytryptaminergic neuronal damage. Other possible mechanisms related to 5-HT uptake inhibitor attenuation of methamphetamine-induced deficits were investigated. Fluoxetine pretreatment prevented the methamphetamine-induced decrease in tryptophan hydroxylase activity: this effect cannot be attributed to altered body temperatures or brain concentrations of methamphetamine which suggests that neither, per se, is sufficient to impair 5-hydroxytryptaminergic neuronal function.

Animals↗

A rapid and reversible change in dopamine transporters induced by methamphetamine.

Because high doses of methamphetamine promote free radical formation, and striatal dopamine transporters are rapidly inactivated by oxidative events, we determined the effect of a single high dose of methamphetamine on dopamine transporter activity in striatal synaptosomes. One hour after methamphetamine administration, dopamine uptake decreased by 48%. This dramatic decline was totally reversed by 24 h after treatment. These findings suggest that methamphetamine reversibly decreases dopamine transporter activity by oxidative mechanisms.

Animals↗

Role of dopamine D1- and NMDA receptors in regulating neurotensin release in the striatum and nucleus accumbens.

Stimulation of dopamine D1-receptors by SKF 82958 increased extracellular neurotensin (NT) levels in the striatum and nucleus accumbens as measured by in vivo microdialysis while blockade of D1-receptors had no effect. Antagonism of NMDA receptors with MK 801 completely prevented the increased NT release induced by D1-stimulation in both structures. Tissue content of striatal NT anterior and posterior to the microdialysis probe was oppositely altered by D1-stimulation: increases were observed in the anterior striatum with decreased NT levels in the posterior striatum.

Animals↗

Comparison of neurotensin responses to MDL 100,907, a selective 5HT2A antagonist, with clozapine and haloperidol.

The unique pharmacological profile of atypical antipsychotics, such as clozapine, suggests that action on non-dopaminergic transmitter systems might contribute to the unique therapeutic benefits of these drugs. In order to test this possibility, the response of neurotensin systems to drugs with antipsychotic potential was examined because of this peptide's putative association with psychiatric disorders. The effects of treatments by haloperidol, clozapine, and MDL 100,907 (a selective 5HT2A antagonist thought to have antipsychotic activity) on NT pathways were determined in various extrapyramidal and limbic regions and compared. The response of neurotensin systems was determined by measuring neurotensin-like immunoreactivity after 1, 2, 4, and 5 drug administrations. It was observed that tissue content of this peptide in caudate and nucleus accumbens regions tended to be elevated after 1 or 2 drug administrations, but had either returned or was returning to control levels after 4 or 5 drug administrations. In general, the extrapyramidal and limbic neurotensin levels responded in a similar manner to clozapine and the 5HT2A antagonist, but differently for haloperidol in most regions examined. An important exception was in the nucleus accumbens, where all three drugs had similar effects on neurotensin tissue levels. These results suggest that 5HT2A receptors exert basal control over some extrapyramidal and limbic neurotensin systems and this interaction might contribute to the antipsychotic effects of these drugs.

Animals↗

Reaction of substituted anthracenes and a butadiene with nitric oxide: product formation determined by EPR spectroscopy.

When nitric oxide (NO), generated from nitric acid and copper, was reacted with a series of 9,10-substituted anthracenes, only 9,10-dimethylanthracene gave EPR detectable nitroxide radicals, although the expected bicyclic nitroxide arising from cheletropic NO addition across the 9,10-positions was not observed. Purity of the NO is crucial as the presence of higher oxides of nitrogen leads to radicals by hydrogen abstraction which are trapped by NO and the resultant nitroso compounds produce stable nitroxides detectable by EPR. In contrast the acyclic system, 3,4-diphenyl-2,5-dimethyl-2,4-hexadiene gives rise to an EPR spectrum consistent with cheletropic NO addition, although higher oxides of nitrogen again mediate the formation of different nitroxides.

Anthracenes↗

Rapid and reversible effects of methamphetamine on dopamine transporters.

Reactive oxygen species decrease dopamine transporter (DAT) function in vitro. Because of this, and the finding that METH administration causes oxygen radical formation in vivo, the effects of METH administration on DAT activity in rat striatum were investigated. A single METH injection caused a dose-dependent (0-15 mg/kg) decrease in [3H]dopamine uptake into striatal synaptosomes prepared 1 h after METH administration; an effect attributable to a decreased Vmax of [3H]dopamine uptake. Similarly, multiple high-dose administrations of METH (10 mg/kg/dose; four doses at 2-h intervals) decreased DAT function. The decreases in DAT activity after either single or multiple METH administrations were reversed 24 h after treatment. [3H]5HT transport into striatal synaptosomes was also affected by METH treatment. Taken together, these data suggest that METH decreases DAT activity, perhaps through a reactive oxygen species-mediated mechanism. These findings may have important implications regarding the role of oxidative events in the physiological regulation of monoaminergic systems.

Animals↗

Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration.

Administration of a single high dose of methamphetamine (METH) causes a rapid and reversible decrease in the activity of the tryptophan hydroxylase (TPH), the rate-limiting enzyme in the synthesis of 5-hydroxytryptamine. This effect can be reversed completely by exposing the METH-impaired enzyme to a reducing environment, which suggests that the decrease in TPH activity is a reversible oxidative consequence of free radical formation. Consistent with this hypothesis, a single METH administration to male rats increased oxygen radical formation, as demonstrated by increased striatal dihydroxybenzoic acid formation after coadministration of salicylate with METH. Prevention of METH-induced hyperthermia attenuated both the increase in dihydroxybenzoic acid formation and the decrease in TPH activity observed 1 h after METH administration. These data suggest that both reactive oxygen species and hyperthermia contribute to the acute decrease in TPH activity which results from a single METH administration.

Animals↗

Exacerbation of methamphetamine-induced neurochemical deficits by melatonin.

Methamphetamine (METH), administered in large, repeated doses, compromises the dopaminergic and serotonergic systems as indicated by prolonged suppression of tyrosine hydroxylase and tryptophan hydroxylase activity and concurrent decreases in the content of dopamine and 5-hydroxytryptamine. Because dopamine is necessary for these dopaminergic and serotonergic deficits we postulated that dopamine and/or its reactive metabolites are responsible for these degenerative alterations. Because we previously demonstrated that in vitro reducing conditions reverse the decrease in tryptophan hydroxylase activity, we reasoned that melatonin, a purported endogenous antioxidant, may alter this response. Rats were treated with METH and/or melatonin and trytophan hydroxylase activity and 5-hydroxytryptamine content were assessed; tyrosine hydroxylase activity and dopamine content were also measured. Not only did melatonin not prevent METH-induced deficits in serotonergic and dopaminergic parameters, but coadministration of melatonin with METH actually enhanced most of the monoaminergic effects of METH. This enhancing effect could not be attributed to alteration of body temperature. Because METH abuse causes insomnia and melatonin is promoted in some countries for insomnia, the implications of the interaction between these two drugs could be clinically important.

Animals↗

Role of endogenous dopamine in the neurochemical deficits induced by methcathinone.

Multiple administrations of methcathinone caused persistent deficits in monoaminergic systems, as reflected by decreases in dopamine and 5-hydroxytryptamine uptake capacity, tissue content and associated rate-limiting synthetic enzyme activities. Because dopamine has been implicated in mediating such effects after administration of related amphetamine analogs, its role in effecting methcathinone-induced monoaminergic neuronal impairment was assessed. A single high-dose administration of methcathinone increased striatal dopamine release, as measured by microdialysis in conscious rats and reflected by increases in striatal neurotensin-like immunoreactivity. Dopaminergic deficits observed 18 hr after a multiple-dose treatment with methcathinone were prevented by pretreatment with the selective D1 antagonist SCH23390 and D2 receptor antagonist eticlopride, but 5-hydroxytryptaminergic deficits were not altered. 5-Hydroxytryptaminergic changes did not occur in animals depleted of striatal dopamine by 6-hydroxydopamine lesions. These results indicate that dopaminergic systems are profoundly affected by methcathinone administration and that dopamine likely contributes to the monoaminergic effects of this stimulant.

Animals↗